Compare Davita Inc (DVA) vs Entegris Inc (ENTG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Entegris Inc — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while Entegris Inc trades at $154.4 (market cap $23.24B). The key difference: Entegris Inc is the larger of the two by market cap, and Entegris Inc pays a 0.26% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | ENTG | |
|---|---|---|
Market Cap | $11.72B | $23.24B |
Sector | Health | Technology |
52-Week High | $240.96 | $184.00 |
52-Week Low | $103.87 | $68.80 |
Enterprise Value | $24.44B | $26.44B |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
ENTG is trading at $152.08, up 6.61% over 24 hours, near its consensus price target of $181.17. The stock shows bullish momentum with strong earnings beats in recent quarters, driven by AI-related semiconductor demand. Technical indicators suggest a bullish trend, though RSI hints at overbought conditions. Revenue growth and margin expansion are supported by increasing chip complexity and purity solutions demand.
Outlook remains positive with analyst consensus favoring Buy (66.67%), but high valuation multiples like P/E of 76.04 pose risks. Key opportunities include sustained AI-driven growth, while risks involve valuation sensitivity and semiconductor cycle volatility. The company's cash flow stability and strategic positioning in advanced segments support long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
